上海交通大学学报（医学版）

›› 2011, Vol. 31 ›› Issue (4): 481-.doi: 10.3969/j.issn.1674-8115.2011.04.023

• 论著（临床研究） • 上一篇    下一篇

吉西他滨联合卡铂在复发性上皮性卵巢癌治疗中的应用

潘一红1, 陶俊贞1, 吕荣伟1, 金芙蓉1, 林慧敏1, 周丹红1, 陶德友2   

  1. 1.台州恩泽医疗集团中心医院妇产科, 台州 318000； 2.台州恩泽医疗集团路桥医院肿瘤科, 台州 318050
  • 出版日期:2011-04-28 发布日期:2011-04-28
  • 通讯作者: 陶德友, 电子信箱: taodeyou2000@yahoo.com.cn。
  • 作者简介:潘一红(1978—), 女, 主治医师, 硕士；电子信箱: tdy8896@yahoo.com.cn。

Application of gemeitabine plus carboplatin in treatment of recurrent epithelial ovarian cancer

PAN Yi-hong1, TAO Jun-zhen1, LV Rong-wei1, JIN Fu-rong1, LIN Hui-min1, ZHOU Dan-hong1, TAO De-you2   

  1. 1.Department of Obstetrics and Gynecology, Taizhou Central Hospital, Taizhou 318000, China；2.Department of Oncology, Luqiao Central Hospital, Taizhou 318050, China
  • Online:2011-04-28 Published:2011-04-28

PDF (PC)

1320

摘要：

目的 探讨吉西他滨联合卡铂治疗复发性上皮性卵巢癌的有效性和不良反应。方法 对76例复发性上皮性卵巢癌患者应用吉西他滨1 000 mg/m2，第1天和第8天静脉滴注；CBP浓度-时间曲线下面积（AUC）=5，第1天静脉滴注；21天为一个疗程。依据世界卫生组织实体瘤疗效评估标准和国际妇科肿瘤学会卵巢癌疗效判断标准进行疗效评定，并观察化疗后不良反应。结果 76例患者中，完全缓解21例(27.63%)，部分缓解36例(47.37%)，稳定13例（17.11%），进展6例（7.89%）;治疗总有效率75.0%（57/76）。患者无进展生存期平均为4.1个月（2～10个月）。化疗后第8天，中性粒细胞减少、血小板减少、红细胞减少、消化道不良反应的发生率分别84.21%、78.95%、26.32%和86.84%；其他不良反应的发生率均低于20%。无死亡病例。结论 吉西他滨联合卡铂是治疗复发性上皮性卵巢癌的有效方案，临床疗效较好，安全性高，其不良反应可控制，患者可耐受。

关键词: 吉西他滨, 卡铂, 复发性上皮性卵巢癌, 化疗

Abstract:

Objective To investigate the therapeutic effects and adverse effects of gemeitabine plus carboplatin in treatment of recurrent epithelial ovarian cancer. Methods Gemeitabine (1 000 mg/m2) was intravenously administered to 76 patients with recurrent epithelial ovarian cancer on day 1 and day 8. Carboplatin was intravenously administered on day 1 with area under the concentration-time curve of 5. Each course of treatment lasted for 21 d. The efficacy was evaluated by Response Evaluation Criteria in Solid Tumors of World Health Organization and Ovarian Cancer Therapeutic Effect Criteria of International Society of Gynecologic Cancer, and adverse effects after chemotherapy were observed. Results Among the 76 patients, complete remission was achieved in 21(27.63%), partial remission in 36(47.37%), stable disease in 13（17.11%） and progression disease in 6（7.89%）. The overall response rate was 75.0%(57/76). The mean progression-free survival was 4.1 months (2 to 10 months). Eight days after chemotherapy, the prevalences of neutropenia, thrombocytopenia, anemia and gastrointestinal adverse effects were 84.21%, 78.95%, 26.32% and 86.84%, respectively, and the prevalence of each of the other adverse effects was less than 20%. No death occurred. Conclusion Gemeitabine plus carboplatin is an effective regimen for treatment of recurrent recurrent epithelial ovarian cancer, with favorable therapeutic effects, high safety and tolerable adverse effects.

Key words: gemcitabine, carboplatin, recurrent epithelial ovarian cancer, chemotherapy